Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer.
Mikami H, Feng S, Matsuda Y, Ishii S, Naoi S, Azuma Y, Nagano H, Asanuma K, Kayukawa Y, Tsunenari T, Kamikawaji S, Iwabuchi R, Shinozuka J, Yamazaki M, Kuroi H, Ho SSW, Gan SW, Chichili P, Pang CL, Yeo CY, Shimizu S, Hironiwa N, Kinoshita Y, Shimizu Y, Sakamoto A, Muraoka M, Takahashi N, Kawa T, Shiraiwa H, Mimoto F, Kashima K, Kamata-Sakurai M, Ishikawa S, Aburatani H, Kitazawa T, Igawa T. Mikami H, et al. Among authors: iwabuchi r. Cancer Immunol Res. 2024 Apr 1:OF1-OF12. doi: 10.1158/2326-6066.CIR-23-0638. Online ahead of print. Cancer Immunol Res. 2024. PMID: 38563577
Engineering CD3/CD137 dual specificity into a DLL3-targeted T-cell engager enhances T-cell infiltration and efficacy against small cell lung cancer.
Mikami H, Feng S, Matsuda Y, Ishii S, Naoi S, Azuma Y, Nagano H, Asanuma K, Kayukawa Y, Tsunenari T, Kamikawaji S, Iwabuchi R, Shinozuka J, Yamazaki M, Kuroi H, Ho SSW, Gan SW, Chichili P, Pang CL, Yeo CY, Shimizu S, Hironiwa N, Kinoshita Y, Shimizu Y, Sakamoto A, Muraoka M, Takahashi N, Kawa T, Shiraiwa H, Mimoto F, Kashima K, Kamata-Sakurai M, Ishikawa S, Aburatani H, Kitazawa T, Igawa T. Mikami H, et al. Among authors: iwabuchi r. Cancer Immunol Res. 2024 Mar 20. doi: 10.1158/2326-6066.CIR-23-0638. Online ahead of print. Cancer Immunol Res. 2024. PMID: 38558120
Anti-SARS-CoV-2 IgG antibody titer after BNT162b2 mRNA COVID-19 vaccination in Japanese patients who underwent renal replacement therapy, hemodialysis, peritoneal dialysis, and kidney transplantation.
Iwabuchi R, Harada M, Yamada A, Aomura D, Yamada Y, Sonoda K, Nakazawa H, Sakai K, Mizukami E, Hashimoto K, Kamijo Y. Iwabuchi R, et al. Clin Exp Nephrol. 2023 Aug;27(8):660-671. doi: 10.1007/s10157-023-02348-8. Epub 2023 Apr 24. Clin Exp Nephrol. 2023. PMID: 37095343 Free PMC article.
XCR1+ DCs are critical for T cell-mediated immunotherapy of chronic viral infections.
Domenjo-Vila E, Casella V, Iwabuchi R, Fossum E, Pedragosa M, Castellví Q, Cebollada Rica P, Kaisho T, Terahara K, Bocharov G, Argilaguet J, Meyerhans A. Domenjo-Vila E, et al. Among authors: iwabuchi r. Cell Rep. 2023 Feb 28;42(2):112123. doi: 10.1016/j.celrep.2023.112123. Epub 2023 Feb 14. Cell Rep. 2023. PMID: 36795562 Free article.
Comparative analysis of humoral responses to BNT162b2 vaccine among patients with hematologic disorders and organ transplant recipients.
Nakazawa H, Sakai K, Sudo Y, Iwabuchi R, Sakai H, Nishina S, Kawakami T, Kawakami F, Matsuzawa S, Ito T, Kitahara M, Kamijo Y, Umemura T, Ushiki A, Kanai S, Tsuchiya H, Ishida F. Nakazawa H, et al. Among authors: iwabuchi r. Transpl Immunol. 2022 Dec;75:101713. doi: 10.1016/j.trim.2022.101713. Epub 2022 Sep 12. Transpl Immunol. 2022. PMID: 36100196 Free PMC article.
Development of an Inflammatory CD14+ Dendritic Cell Subset in Humanized Mice.
Iwabuchi R, Ide K, Terahara K, Wagatsuma R, Iwaki R, Matsunaga H, Tsunetsugu-Yokota Y, Takeyama H, Takahashi Y. Iwabuchi R, et al. Front Immunol. 2021 Mar 15;12:643040. doi: 10.3389/fimmu.2021.643040. eCollection 2021. Front Immunol. 2021. PMID: 33790912 Free PMC article.
22 results